Xintian Pharmaceutical: Plans to sell no more than 1% of repurchased shares.

Xintian Pharmaceuticals announced that the board of directors will convene on April 2, 2026 to review and approve the proposal to sell a portion of the repurchased shares through centralized competitive trading. According to the previously disclosed "Continued Share Repurchase Report and First Repurchase Announcement," the board of directors agreed that the company will sell up to 2.441 million repurchased shares, accounting for 1% of the total shares, within three months after 15 trading days from the date of the announcement, namely from April 28, 2026 to July 27, 2026. The number of repurchased shares to be sold this time does not exceed the quantity specified in the company's "Share Repurchase Report" for sale through centralized competitive trading.